Drugs /

jab-21822

Back to Drugs List

Overview

Clinical Trials

View Clinical Trials for jab-21822

Jab-21822 has been investigated in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial investigating jab-21822, 1 is phase 1/phase 2 (1 open).

KRAS G12C is the most frequent biomarker inclusion criterion for jab-21822 clinical trials.

Malignant solid tumor is the most common disease being investigated in jab-21822 clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Jab-21822
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating jab-21822 and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Drug Target(s) [2]:
KRAS

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.